Pandemic & Infectious Disease — 2026-05-01
This week brought a wave of vaccine approvals and pipeline advances, with the FDA greenlighting Bavarian Nordic's chikungunya vaccine for those 12 and older and the agency announcing a major new Real-Time Clinical Trials initiative. STAT News experts weighed in on COVID-19's declining severity and who still benefits from boosters, while Travel Health Pro flagged active outbreaks across 19 countries for travelers to monitor. A global TB vaccine summit reviewed accelerators underway to bring novel vaccines to adults and adolescents.
Pandemic & Infectious Disease — 2026-05-01
Active Outbreak Tracker
Worldwide Travel Health Alerts — 19 Countries
- Status: Active monitoring across 19 countries as of May 1, 2026
- Key Development: Travel Health Pro issued its latest global health alert roundup, identifying active outbreaks in 19 countries that travelers should be aware of. The alerts cover a broad spectrum of infectious disease risks across multiple continents.
- Response: Health authorities are advising travelers to check national travel health guidance before departure and consult country-specific vaccination and precaution recommendations.
Tuberculosis (TB) — Global
- Status: Ongoing global burden; GlobalData epidemiologists project TB cases across 16 major markets to reach 4.5 million by 2033
- Key Development: On April 29, the WHO convened a technical summit on progress to accelerate availability of novel TB vaccines for adults and adolescents. Participants reviewed activities underway through the TB Vaccine Accelerator working groups and other initiatives aimed at closing the vaccine gap.
- Response: WHO and partners are coordinating accelerator programs targeting adults and adolescents, a population historically underserved by TB prevention tools.
%2Fcountries%2Fmongolia%2Fon-site-review-of-tb-service-related-data-(resized).tmb-1200v.png%3Fsfvrsn%3D2aecb665_1)
Respiratory Viruses (COVID-19, Flu, RSV) — United States
- Status: Very low; as of April 24, 2026, the CDC reported that the amount of acute respiratory illness causing people to seek health care is very low
- Key Development: Seasonal respiratory illness has subsided to minimal levels across the United States. COVID-19, influenza, and RSV are all tracking at low activity nationally and in most states heading into May.
- Response: The CDC continues weekly monitoring via its Respiratory Illnesses Data Channel. The FDA's Vaccines and Related Biological Products Advisory Committee has scheduled a public meeting to deliberate on the 2026–2027 COVID-19 vaccine antigen composition.
Vaccine & Treatment Pipeline
- Chikungunya Vaccine (Bavarian Nordic): The FDA approved Bavarian Nordic's chikungunya vaccine for individuals 12 years and older, based on positive Phase 3 clinical trial results. The approval offers an effective prevention option for travelers and others at risk of the mosquito-borne illness.
- Intranasal COVID-19 Vaccine (NextGen): An intranasal and inhaled version of a COVID-19 vaccine is heading into a Phase 1 trial in the United States as of April 30. The candidate represents part of the broader next-generation vaccine effort aimed at improving mucosal immunity and ease of administration.
- Real-Time Clinical Trials (RTCT) Initiative (FDA): On April 28, the FDA announced two major implementation steps for its Real-Time Clinical Trials initiative, including proof-of-concept demonstrations and an upcoming pilot program. By streaming live trial data to regulators, the agency aims to cut years off approval timelines for life-saving treatments including vaccines and infectious disease therapeutics.
Expert Analysis
COVID-19's threat profile has shifted markedly, according to a new expert analysis published by STAT News on April 27. Specialists examined why the virus's severity has declined dramatically and who still derives meaningful benefit from booster shots. The piece explores whether COVID-19 has effectively transitioned into something more akin to common colds or seasonal flu for most people—a question that carries enormous implications for vaccination policy and public health messaging going forward.
Separately, the FDA's announcement of the 2026–2027 COVID-19 vaccine composition advisory meeting—published in the Federal Register on April 27—signals that regulators are already working ahead of the next respiratory season. The advisory committee will deliberate on what antigen composition is most appropriate to protect against circulating strains, an annual process that mirrors influenza vaccine strain selection. The FDA is soliciting public comments as part of the process, reflecting continued institutional investment in COVID-19 vaccine optimization despite the virus's diminished overall severity.
On the TB front, the WHO's global technical summit (April 29) convened experts to review accelerator programs aimed at making novel TB vaccines accessible to the adult and adolescent populations most at risk. TB remains one of the leading infectious disease killers globally—with case projections still on an upward trend through 2033 across major markets—and the lack of an effective adult vaccine has long been identified as a critical gap by global health authorities. The summit represents a renewed push to close this gap before case counts grow further.
Global Health Security
FDA Real-Time Clinical Trials Initiative: On April 28, the FDA unveiled proof-of-concept demonstrations and details of an upcoming pilot program as part of its Real-Time Clinical Trials initiative. By allowing regulators to monitor streaming trial data in real time rather than waiting for trial completion, the program could fundamentally accelerate the path from clinical testing to regulatory approval for vaccines and treatments targeting emerging pathogens.
2026–2027 COVID-19 Vaccine Composition Advisory Meeting: The FDA published notice in the Federal Register on April 27 of a forthcoming advisory committee meeting to determine the antigen composition of the U.S. 2026–2027 COVID-19 vaccine formula. A public docket has been established and comments are being solicited, marking the continuation of the annual strain-review process that helps ensure vaccines remain matched to circulating variants.
WHO TB Vaccine Accelerator Summit: The WHO convened a two-day global technical forum (April 29) with international partners reviewing novel TB vaccine development pipelines for adults and adolescents. With TB cases projected to rise toward 4.5 million annually across 16 major markets by 2033, the working group meetings and accelerator initiatives represent a concerted multilateral push to prevent a worsening epidemic.
What to Watch Next
- 2026–2027 COVID-19 Vaccine Strain Selection: The FDA's advisory committee meeting on antigen composition is a key upcoming milestone. The outcome will shape which COVID-19 vaccines are recommended and manufactured for the next respiratory season—watch for committee dates and public hearing announcements.
- FDA Real-Time Clinical Trials Pilot Program: The agency's RTCT pilot is moving from proof-of-concept to active program status. Early results from this initiative could set a precedent for how infectious disease vaccines and therapies are reviewed and approved, potentially cutting years off timelines for the next pandemic response.
- Novel TB Vaccines in Phase 3: Several TB vaccine candidates are advancing through late-stage trials, targeting adults and adolescents who lack any currently licensed option. Post-summit momentum at WHO could translate into faster regulatory pathways or coordinated funding—progress here could represent one of global health's most significant breakthroughs in decades.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
